ACU193 is the first monoclonal antibody to enter a clinical trial that was discovered and is being developed to selectively target toxic amyloid-beta oligomers (AβOs) Acumen announced dosing of first ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results